Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2015

01.03.2015 | Clinical

The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal

verfasst von: Maarten F. Bijlsma, Hanneke W. M. van Laarhoven

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

A nearly universal feature of pancreatic ductal adenocarcinoma (PDAC) is an extensive presence of activated stroma. This stroma is thought to aid in various tumor-promoting processes and hampers response to therapy. Here, we aim to evaluate the evidence that supports this role of the stroma in PDAC with functional experiments in relevant models, discuss the clinical trials that have aimed to target the stroma in this disease, and examine recent work that explains why these clinical trials based on stroma-targeting strategies have thus far not achieved the expected success. We systematically searched PubMed through August 2014 with no restrictions to identify published peer-reviewed research articles assessing the effect of targeting the stroma on tumor growth or metastases in preclinical animal models. Five hundred and thirty articles were extracted of which 31 were included in the analysis. Unfortunately, due to the large variety in models and outcome measures, we could not perform a meta-analysis of our data. We find that despite an abundance of positive outcomes reported in previous studies on stroma targeting, a strong discrepancy exists with the outcomes of clinical trials and the more recent preclinical work that is in line with these trials. We explain the incongruities by the duration of stroma targeting and propose that chronic stroma targeting treatment is possibly detrimental in the treatment of this disease.
Literatur
1.
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74, 2913–2921. doi:10.​1158/​0008-5472.​CAN-14-0155.CrossRefPubMed
2.
3.
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., Gutberlet, K., Kettner, E., Schmalenberg, H., Weigang-Koehler, K., Bechstein, W. O., Niedergethmann, M., Schmidt-Wolf, I., Roll, L., Doerken, B., & Riess, H. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 297, 267–277. doi:10.​1001/​jama.​297.​3.​267.CrossRefPubMed
4.
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., Wente, M. N., Izbicki, J. R., Friess, H., Lerch, M. M., Dervenis, C., Olah, A., Butturini, G., Doi, R., Lind, P. A., Smith, D., Valle, J. W., Palmer, D. H., Buckels, J. A., Thompson, J., McKay, C. J., & Rawcliffe, C. L. (2010). Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA, 304, 1073–1081.CrossRefPubMed
5.
Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., Shimada, M., & Kanemitsu, K. (2009). A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer, 101, 908–915. doi:10.​1038/​sj.​bjc.​6605256.CrossRefPubMedPubMedCentral
6.
Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., & Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15, 2403–2413.PubMed
7.
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1960–1966. doi:10.​1200/​JCO.​2006.​07.​9525.CrossRefPubMed
8.
Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J. L., Gourgou-Bourgade, S., de la Fouchardiere, C., Bennouna, J., Bachet, J. B., Khemissa-Akouz, F., Pere-Verge, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New English Journal Medicine, 364, 1817–825. doi:10.​1056/​NEJMoa1011923. 364.CrossRef
9.
Van Laethem, J. L., Verslype, C., Iovanna, J. L., Michl, P., Conroy, T., Louvet, C., Hammel, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., Van, T. G., Bachet, J. B., Marechal, R., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J. P., & Lutz, M. (2012). ew strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Annals of Oncology, 23, 570–576. doi:10.​1093/​annonc/​mdr351.CrossRefPubMed
10.
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B., Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D., Gray, J. W., Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B., Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D., & Gray, J. W. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 17(17), 500–503. doi:10.​1038/​nm.​2344.CrossRefPubMedPubMedCentral
11.
12.
13.
Wu, J., Jiao, Y., Dal, M. M., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M. G., Wolfgang, C. L., Canto, M. I., Schulick, R. D., Edil, B. H., Choti, M. A., Adsay, V., Klimstra, D. S., Offerhaus, G. J., Klein, A. P., Kopelovich, L., Carter, H., Karchin, R., Allen, P. J., Schmidt, C. M., Naito, Y., Diaz, L. A., Jr., Kinzler, K. W., Papadopoulos, N., Hruban, R. H., & Vogelstein, B. (2011). Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 108, 21188–21193. doi:10.​1073/​pnas.​1118046108.CrossRefPubMedPubMedCentral
14.
15.
16.
Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M. C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A. M., Wu, J., Chang, D. K., Cowley, M. J., Gardiner, B. B., Song, S., Harliwong, I., Idrisoglu, S., Nourse, C., Nourbakhsh, E., Manning, S., Wani, S., Gongora, M., Pajic, M., Scarlett, C. J., Gill, A. J., Pinho, A. V., Rooman, I., Anderson, M., Holmes, O., Leonard, C., Taylor, D., Wood, S., Xu, Q., Nones, K., Fink, J. L., Christ, A., Bruxner, T., Cloonan, N., Kolle, G., Newell, F., Pinese, M., Mead, R. S., Humphris, J. L., Kaplan, W., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chou, A., Chin, V. T., Chantrill, L. A., Mawson, A., Samra, J. S., Kench, J. G., Lovell, J. A., Daly, R. J., Merrett, N. D., Toon, C., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Kakkar, N., Zhao, F., Wu, Y. Q., Wang, M., Muzny, D. M., Fisher, W. E., Brunicardi, F. C., Hodges, S. E., Reid, J. G., Drummond, J., Chang, K., Han, Y., Lewis, L. R., Dinh, H., Buhay, C. J., Beck, T., Timms, L., Sam, M., Begley, K., Brown, A., Pai, D., Panchal, A., Buchner, N., De, B. R., Denroche, R. E., Yung, C. K., Serra, S., Onetto, N., Mukhopadhyay, D., Tsao, M. S., Shaw, P. A., Petersen, G. M., Gallinger, S., Hruban, R. H., Maitra, A., Iacobuzio-Donahue, C. A., Schulick, R. D., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Capelli, P., Corbo, V., Scardoni, M., Tortora, G., Tempero, M. A., Mann, K. M., Jenkins, N. A., Perez-Mancera, P. A., Adams, D. J., Largaespada, D. A., Wessels, L. F., Rust, A. G., Stein, L. D., Tuveson, D. A., Copeland, N. G., Musgrove, E. A., Scarpa, A., Eshleman, J. R., Hudson, T. J., Sutherland, R. L., Wheeler, D. A., Pearson, J. V., McPherson, J. D., Gibbs, R. A., & Grimmond, S. M. (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491, 399–405. doi:10.​1038/​nature11547.CrossRefPubMedPubMedCentral
17.
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J. C., Galban, S., Galban, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & di Pasca, M. M. (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. Journal of Clinical Investigation, 122, 639–653. doi:10.​1172/​JCI59227.CrossRefPubMedPubMedCentral
18.
Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., Hruban, R. H., Klein, A. P., Jones, S., Velculescu, V., Wolfgang, C. L., & Iacobuzio-Donahue, C. A. (2012). Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clinical Cancer Research, 18, 6339–6347. doi:10.​1158/​1078-0432.​CCR-12-1215.CrossRefPubMedPubMedCentral
19.
Donahue, T. R., Tran, L. M., Hill, R., Li, Y., Kovochich, A., Calvopina, J. H., Patel, S. G., Wu, N., Hindoyan, A., Farrell, J. J., Li, X., Dawson, D. W., & Wu, H. (2012). Integrative survival-based molecular profiling of human pancreatic cancer. Clinical Cancer Research, 18, 1352–1363. doi:10.​1158/​1078-0432.​CCR-11-1539.CrossRefPubMed
20.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Iacobuzio-Donahue, C. A. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467, 1114–1117. doi:10.​1038/​nature09515.CrossRefPubMedPubMedCentral
21.
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321, 1801–1806. doi:10.​1126/​science.​1164368.CrossRefPubMedPubMedCentral
22.
Erkan, M., Reiser-Erkan, C., Michalski, C. W., Kong, B., Esposito, I., Friess, H., & Kleeff, J. (2012). The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Current Molecular Medicine, 12, 288–303.CrossRefPubMed
23.
24.
Erkan, M., Reiser-Erkan, C., Michalski, C. W., & Kleeff, J. (2010). Tumor microenvironment and progression of pancreatic cancer. Experimental Oncology, 32, 128–131.PubMed
25.
Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., De Jesus-Acosta, A., Sharma, P., Heidari, P., Mahmood, U., Chin, L., Moses, H. L., Weaver, V. M., Maitra, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25, 719–734. doi:10.​1016/​j.​ccr.​2014.​04.​005.CrossRefPubMedPubMedCentral
26.
Rockwell, S., Dobrucki, I. T., Kim, E. Y., Marrison, S. T., & Vu, V. T. (2009). Hypoxia and radiation therapy: past history, ongoing research, and future promise. Current Molecular Medicine, 9, 442–458.CrossRefPubMedPubMedCentral
27.
Kleeff, J., Beckhove, P., Esposito, I., Herzig, S., Huber, P. E., Lohr, J. M., & Friess, H. (2007). Pancreatic cancer microenvironment. International Journal of Cancer, 121, 699–705. doi:10.​1002/​ijc.​22871.CrossRefPubMed
28.
McCarroll, J. A., Naim, S., Sharbeen, G., Russia, N., Lee, J., Kavallaris, M., Goldstein, D., & Phillips, P. A. (2014). Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Frontiers in Physiology, 5, 141. doi:10.​3389/​fphys.​2014.​00141.PubMedPubMedCentral
29.
30.
Erkan, M., Reiser-Erkan, C., Michalski, C. W., Deucker, S., Sauliunaite, D., Streit, S., Esposito, I., Friess, H., & Kleeff, J. (2009). Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia, 11, 497–508.CrossRefPubMedPubMedCentral
31.
Sparmann, G., Kruse, M. L., Hofmeister-Mielke, N., Koczan, D., Jaster, R., Liebe, S., Wolff, D., & Emmrich, J. (2010). Bone marrow-derived pancreatic stellate cells in rats. Cell Research, 20, 288–298. doi:10.​1038/​cr.​2010.​10.CrossRefPubMed
32.
Akita, S., Kubota, K., Kobayashi, A., Misawa, R., Shimizu, A., Nakata, T., Yokoyama, T., Takahashi, M., & Miyagawa, S. (2012). Role of bone marrow cells in the development of pancreatic fibrosis in a rat model of pancreatitis induced by a choline-deficient/ethionine-supplemented diet. Biochemical and Biophysical Research Communications, 420, 743–749. doi:10.​1016/​j.​bbrc.​2012.​03.​060.CrossRefPubMed
33.
Scarlett, C. J., Colvin, E. K., Pinese, M., Chang, D. K., Morey, A. L., Musgrove, E. A., Pajic, M., Apte, M., Henshall, S. M., Sutherland, R. L., Kench, J. G., & Biankin, A. V. (2011). Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PloS One, 6, e26088. doi:10.​1371/​journal.​pone.​0026088.CrossRefPubMedPubMedCentral
34.
35.
36.
Kadaba, R., Birke, H., Wang, J., Hooper, S., Andl, C. D., Di, M. F., Soylu, E., Ghallab, M., Bor, D., Froeling, F. E., Bhattacharya, S., Rustgi, A. K., Sahai, E., Chelala, C., Sasieni, P., & Kocher, H. M. (2013). Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. Journal of Pathology, 230, 107–117. doi:10.​1002/​path.​4172.CrossRefPubMedPubMedCentral
37.
Coleman, S. J., Chioni, A. M., Ghallab, M., Anderson, R. K., Lemoine, N. R., Kocher, H. M., & Grose, R. P. (2014). Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Molecular Medicine, 6, 467–481. doi:10.​1002/​emmm.​201302698.CrossRefPubMedPubMedCentral
38.
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, b2700.CrossRefPubMedPubMedCentral
39.
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Fernandez-del, C. C., Yajnik, V., Antoniu, B., McMahon, M., Warshaw, A. L., & Hebrok, M. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425, 851–856. doi:10.​1038/​nature02009.CrossRefPubMedPubMedCentral
40.
Heretsch, P., Tzagkaroulaki, L., & Giannis, A. (2010). Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives. Angewandte Chemie International Edition in English, 49, 3418–3427. doi:10.​1002/​anie.​200906967.CrossRef
41.
Ericson, J., Morton, S., Kawakami, A., Roelink, H., & Jessell, T. M. (1996). Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell, 87, 661–673.CrossRefPubMed
42.
43.
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., Denicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Ruckert, F., Grutzmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J., & Tuveson, D. A. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324, 1457–1461. doi:10.​1126/​science.​1171362.CrossRefPubMedPubMedCentral
44.
Nakamura, K., Sasajima, J., Mizukami, Y., Sugiyama, Y., Yamazaki, M., Fujii, R., Kawamoto, T., Koizumi, K., Sato, K., Fujiya, M., Sasaki, K., Tanno, S., Okumura, T., Shimizu, N., Kawabe, J., Karasaki, H., Kono, T., Ii, M., Bardeesy, N., Chung, D. C., & Kohgo, Y. (2010). Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PloS One, 5, e8824. doi:10.​1371/​journal.​pone.​0008824.CrossRefPubMedPubMedCentral
45.
46.
Lonardo, E., Frias-Aldeguer, J., Hermann, P. C., & Heeschen, C. (2012). Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle, 11, 1282–1290. doi:10.​4161/​cc.​19679.CrossRefPubMed
47.
Kayed, H., Meyer, P., He, Y., Kraenzlin, B., Fink, C., Gretz, N., Schoenberg, S. O., & Sadick, M. (2012). Evaluation of the metabolic response to cyclopamine therapy in pancreatic cancer xenografts using a clinical PET-CT system. Translational Oncology, 5, 335–343.CrossRefPubMedPubMedCentral
48.
Chang, Q., Foltz, W. D., Chaudary, N., Hill, R. P., & Hedley, D. W. (2013). Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. International Journal of Cancer, 133, 225–234. doi:10.​1002/​ijc.​28006.CrossRefPubMed
49.
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., Zhang, H., Soon-Shiong, P., Shi, T., Rajeshkumar, N. V., Maitra, A., & Hidalgo, M. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology, 29, 4548–4554. doi:10.​1200/​JCO.​2011.​36.​5742.CrossRef
50.
Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., Ellenrieder, V., Jodrell, D. I., & Tuveson, D. A. (2014). SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut, 63, 974–983. doi:10.​1136/​gutjnl-2013-305559.CrossRefPubMedPubMedCentral
51.
Alvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megias, D., Guerra, C., Munoz, M., Quijano, Y., Cubillo, A., Rodriguez-Pascual, J., Plaza, C., de Vicente, E., Prados, S., Tabernero, S., Barbacid, M., Lopez-Rios, F., & Hidalgo, M. (2013). Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. British Journal of Cancer, 109, 926–933. doi:10.​1038/​bjc.​2013.​415.CrossRefPubMedPubMedCentral
52.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., Pilarsky, C., Jodrell, D. I., Spong, S. M., & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 110, 12325–12330. doi:10.​1073/​pnas.​1300415110.CrossRefPubMedPubMedCentral
53.
54.
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., Lolkema, M. P., Jiang, P., Kultti, A., Thompson, C. B., Maneval, D. C., Jodrell, D. I., Frost, G. I., Shepard, H. M., Skepper, J. N., & Tuveson, D. A. (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 62, 112–120. doi:10.​1136/​gutjnl-2012-302529.CrossRefPubMedPubMedCentral
55.
56.
Hajime, M., Shuichi, Y., Makoto, N., Masanori, Y., Ikuko, K., Atsushi, K., Mutsuo, S., & Keiichi, T. (2007). Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. International Journal of Cancer, 120, 2704–2709. doi:10.​1002/​ijc.​22349.CrossRefPubMed
57.
58.
Kozono, S., Ohuchida, K., Eguchi, D., Ikenaga, N., Fujiwara, K., Cui, L., Mizumoto, K., & Tanaka, M. (2013). Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Research, 73, 2345–2356. doi:10.​1158/​0008-5472.​CAN-12-3180.CrossRefPubMed
59.
Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America 104, 10.​1073/​pnas.​0611660104
60.
Medicherla, S., Li, L., Ma, J. Y., Kapoun, A. M., Gaspar, N. J., Liu, Y. W., Mangadu, R., O’Young, G., Protter, A. A., Schreiner, G. F., Wong, D. H., & Higgins, L. S. (2007). Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Research, 27, 4149–4157.PubMed
61.
Gore, A. J., Deitz, S. L., Palam, L. R., Craven, K. E., & Korc, M. (2014). Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation. Journal of Clinical Investigation, 124, 338–352. doi:10.​1172/​JCI71526.CrossRefPubMedPubMedCentral
62.
63.
Masamune, A., Hamada, S., Kikuta, K., Takikawa, T., Miura, S., Nakano, E., & Shimosegawa, T. (2013). The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scandinavian Journal of Gastroenterology, 48, 602–609. doi:10.​3109/​00365521.​2013.​777776.CrossRefPubMed
64.
Raykov, Z., Grekova, S. P., Bour, G., Lehn, J. M., Giese, N. A., Nicolau, C., & Aprahamian, M. (2014). Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. International Journal of Cancer, 134, 2572–2582. doi:10.​1002/​ijc.​28597.CrossRefPubMed
65.
Martinez-Bosch, N., Fernandez-Barrena, M. G., Moreno, M., Ortiz-Zapater, E., Munne-Collado, J., Iglesias, M., Andre, S., Gabius, H. J., Hwang, R. F., Poirier, F., Navas, C., Guerra, C., Fernandez-Zapico, M. E., & Navarro, P. (2014). Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Research, 74, 3512–3524. doi:10.​1158/​0008-5472.​CAN-13-3013.CrossRefPubMedPubMedCentral
66.
Feig, C., Jones, J. O., Kraman, M., Wells, R. J., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 110, 20212–20217. doi:10.​1073/​pnas.​1320318110.CrossRefPubMedPubMedCentral
67.
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., Ikenoue, T., Tateishi, K., Wright, C. V., Koike, K., Omata, M., & Moses, H. L. (2011). Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Journal of Clinical Investigation, 121, 4106–4117. doi:10.​1172/​JCI42754.CrossRefPubMedPubMedCentral
68.
69.
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., Westphalen, C. B., Kitajewski, J., Fernandez-Barrena, M. G., Fernandez-Zapico, M. E., Iacobuzio-Donahue, C., Olive, K. P., & Stanger, B. Z. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 25, 735–747. doi:10.​1016/​j.​ccr.​2014.​04.​021.CrossRefPubMedPubMedCentral
70.
Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, Nagle JM, Deshpande V, Boucher Y, Kato T, Chen JK, Willmann JK, Bardeesy N, Beachy PA (2014) Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A 111, 10.​1073/​pnas.​1411679111
71.
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van, C. E., Wei, X., Iglesias, J., & Renschler, M. F. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 369, 1691–1703. doi:10.​1056/​NEJMoa1304369.CrossRef
72.
Goldstein, D., El Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., Tortora, G., Van Laethem, J. L., Young, R., Wei, X., Lu, B., Romano, A., & Von Hoff, D. D. (2014). Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. Journal of Clinical Oncology Meeting Abstracts, 32, 178.
73.
74.
Catenacci, D. V. T., Bahari, N., Edelman, M. J., Nattam, S. R., de Wilton, M. R., Kaubisch, A., Wallace, J. A., Cohen, D. J., Stiff, P. J., Sleckman, B. G., Thomas, S. P., Lenz, H. J., Henderson, L., Zagaya, C., Vannier, M., Karrison, T., Stadler, W. M., & Kindler, H. L. (2012). A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. Journal of Clinical Oncology Meeting Abstracts, 30, 4022.
75.
Richards, D. A., Stephenson, J., Wolpin, B. M., Becerra, C., Hamm, J. T., Messersmith, W. A., Devens, S., Cushing, J., Schmalbach, T., & Fuchs, C. S. (2012). A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. Journal of Clinical Oncology Meeting Abstracts, 30, 213.
76.
Palmer, S. R., Erlichman, C., Fernandez-Zapico, M., Qi, Y., Almada, L., McCleary-Wheeler, A., Borad, M. J., Molina, J. R., Grothey, H. C., Pitot, H. C., Jatoi, A., Northfelt, D. W., McWilliams, R., Okuno, H., Haluska, P., Kim, G. P., & Colon-Otero, G. (2011). Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. Journal of Clinical Oncology Meeting Abstracts, 29, 3092.
77.
De Jesus-Acosta, A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Maitra, A., Rasheed, Z., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., Bolejack, V., Yabuuchi, S., & Laheru, D. A. (2014). A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). J Clinical Oncology Meeting Abstracts, 32, 257.
78.
79.
Damhofer, H., Medema, J. P., Veenstra, V. L., Badea, L., Popescu, I., Roelink, H., & Bijlsma, M. F. (2013). Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. Molecular Oncology, 7, 1031–1042. doi:10.​1016/​j.​molonc.​2013.​08.​004.CrossRefPubMed
80.
Flaberg, E., Markasz, L., Petranyi, G., Stuber, G., Dicso, F., Alchihabi, N., Olah, E., Csizy, I., Jozsa, T., Andren, O., Johansson, J. E., Andersson, S. O., Klein, G., & Szekely, L. (2011). High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. International Journal of Cancer, 128, 2793–2802. doi:10.​1002/​ijc.​25612.CrossRefPubMed
81.
82.
Harsha, H. C., Kandasamy, K., Ranganathan, P., Rani, S., Ramabadran, S., Gollapudi, S., Balakrishnan, L., Dwivedi, S. B., Telikicherla, D., Selvan, L. D., Goel, R., Mathivanan, S., Marimuthu, A., Kashyap, M., Vizza, R. F., Mayer, R. J., Decaprio, J. A., Srivastava, S., Hanash, S. M., Hruban, R. H., & Pandey, A. (2009). A compendium of potential biomarkers of pancreatic cancer. PLoS Medicine, 6, e1000046. doi:10.​1371/​journal.​pmed.​1000046.CrossRefPubMedPubMedCentral
83.
84.
Lonardo, E., Hermann, P. C., Mueller, M. T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J. C., Torres-Ruiz, R., Garcia, E., Hidalgo, M., Cebrian, D. A., Heuchel, R., Lohr, M., Berger, F., Bartenstein, P., Aicher, A., & Heeschen, C. (2011). Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell, 9, 433–446. doi:10.​1016/​j.​stem.​2011.​10.​001.CrossRefPubMed
Metadaten
Titel
The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
verfasst von
Maarten F. Bijlsma
Hanneke W. M. van Laarhoven
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9541-1

Weitere Artikel der Ausgabe 1/2015

Cancer and Metastasis Reviews 1/2015 Zur Ausgabe

OriginalPaper

Targeted immune therapy of ovarian cancer

OriginalPaper

Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies

OriginalPaper

Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma

EditorialNotes

Preface

OriginalPaper

Proteomics of ovarian cancer: functional insights and clinical applications

OriginalPaper

Maintenance chemotherapy in the management of epithelial ovarian cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise